IP Library Granted Patent US 10,092,538
Granted Patent B2
US 10,092,538 · App. 15/787,978 · Granted Oct 9, 2018

Suppositories comprising cannabinoids

Inventors: Lekhram Changoer (Ridderkerk, NL); George Anastassov (New York, NY)
Assignee: Axim Biotechnologies, Inc.
A61K31/352A61K9/025A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,538
App. No.
15/787,978
Granted
Oct 9, 2018
Kind
B2
Abstract

This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.

Claims (22)

1. A suppository composition comprising:

at least one cannabinoid at 0.1% to 50% by weight of the total composition;

at least one sugar alcohol or sugar at 15% to 25% by weight of the total composition;

at least one fatty base suitable for suppository formulation selected from the group consisting of glycerol ricinoleate, hydrogenated coco-glycerin, and ceteareth-25 at 60% to 80% by weight of the total composition; and

at least one non-ionic surfactant selected from the group consisting of ceteareth-15 and ceteareth-17 at 2% to 10% by weight of the total composition,

wherein the at least one cannabinoid is encapsulated into hyaluronic acid derivatives and tocopherol nanolattice, and

wherein the composition is packaged in a suppository mold.

2. The suppository composition of claim 1 , wherein the at least one cannabinoid is THCV.

3. The suppository composition of claim 1 , wherein the at least one cannabinoid is THC and wherein THC comprises 0.1% to 2% by weight of the total composition.

4. The suppository composition of claim 1 , wherein the at least one cannabinoid is from natural sources or synthetic.

5. The suppository composition of claim 1 , wherein the at least one cannabinoid is nanoencapsulated into particles.

6. The suppository composition of claim 5 , wherein the particles are of size 20-40 nm.

7. The suppository composition of claim 1 , wherein the hyaluronic acid derivative is sodium oleyl hyaluronate.

8. The suppository composition of claim 1 , wherein the at least one sugar is maltose and wherein the at least one sugar is provided in micronized form.

9. The suppository composition of claim 1 , wherein the at least one sugar alcohol is isomalt and wherein the at least one sugar alcohol is provided in micronized form.

10. A method to treat or alleviate nausea or vomiting, comprising administering the suppository of claim 1 to a mammal 1-6 times a day as needed.

11. The method of claim 10 , wherein the nausea or vomiting is chemotherapy related nausea or vomiting.

12. A method to treat or alleviate pain, comprising administering the suppository according to claim 1 to a mammal 1-6 times a day or as needed.

13. The method of claim 12 , wherein the pain is menstrual pain.

14. A method to treat or alleviate post-operative ileus, comprising administering the suppository according to claim 1 to a mammal 1-6 times a day or as needed.

15. A method to treat or alleviate intestinal inflammation, comprising administering the suppository according to claim 1 to a mammal 1-6 times a day or as needed.

16. The method of claim 15 , wherein the intestinal inflammation is irritable bowel syndrome or inflammatory bowel disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: AXIM BIOTECHNOLOGIES, INC.
To: APIRX PHARMACEUTICAL USA, LLC
Reel/Frame 052752/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2017
From: CHANGOER, LEKHRAM; ANASTASSOV, GEORGE
To: AXIM BIOTECHNOLOGIES, INC.
Reel/Frame 043949/0489 →
Continuity (2)
Provisional Application 62411067 · Oct 21, 2016
Related Publication 20180110753A1 · Apr 26, 2018